Pregnancy After Breast Cancer in Patients With Germline

Adult BRCA1 Protein / genetics BRCA2 Protein / genetics Breast Neoplasms / complications Congenital Abnormalities / etiology Disease-Free Survival Female Germ-Line Mutation Humans Live Birth Pregnancy Pregnancy Complications / etiology Pregnancy Rate Reproductive Health Retrospective Studies Risk Assessment Risk Factors Time Factors

Journal

Journal of clinical oncology : official journal of the American Society of Clinical Oncology
ISSN: 1527-7755
Titre abrégé: J Clin Oncol
Pays: United States
ID NLM: 8309333

Informations de publication

Date de publication:
10 09 2020
Historique:
pubmed: 17 7 2020
medline: 25 2 2021
entrez: 17 7 2020
Statut: ppublish

Résumé

Young women with germline This is an international, multicenter, hospital-based, retrospective cohort study. Eligible patients were diagnosed between January 2000 and December 2012 with invasive early breast cancer at age ≤ 40 years and harbored deleterious germline Of 1,252 patients with germline Pregnancy after breast cancer in patients with germline

Identifiants

DOI: 10.1200/JCO.19.02399 PMID: 32673153
pubmed: 32673153
doi: 10.1200/JCO.19.02399
doi:

Substances chimiques

BRCA1 Protein 0
BRCA1 protein, human 0
BRCA2 Protein 0
BRCA2 protein, human 0

Banques de données

ClinicalTrials.gov
['NCT03673306']

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3012-3023

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Auteurs

Matteo Lambertini (M)

Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genoa, Genoa, Italy.
Department of Medical Oncology, UOC Clinica di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Lieveke Ameye (L)

Data Centre, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium.

Anne-Sophie Hamy (AS)

Department of Medical Oncology, Institut Curie, Paris, France.

Anna Zingarello (A)

Département Médecine Oncologique, Institut Gustave Roussy, Université Paris-Saclay, Villejuif, France.

Philip D Poorvu (PD)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.

Estela Carrasco (E)

Hereditary Cancer Genetics Group, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.

Albert Grinshpun (A)

Sharett Institute of Oncology, Hadassah-Hebrew University Medical Center, Jerusalem, Israel.

Sileny Han (S)

Multidisciplinary Breast Center, Department of Gynaecology, University Hospitals Leuven, Department of Oncology, KU Leuven, Leuven, Belgium.

Christine Rousset-Jablonski (C)

Department of Surgery, Centre Léon Bérard, Lyon, France.

Alberta Ferrari (A)

Department of Surgical Sciences, General Surgery III-Breast Surgery, Fondazione IRCCS Policlinico San Matteo, and Department of Clinical Surgical Sciences, University of Pavia, Pavia, Italy.

Shani Paluch-Shimon (S)

Breast Oncology Unit, Shaare Zedek Medical Centre, Jerusalem, Israel.

Laura Cortesi (L)

Department of Oncology and Haematology, Azienda Ospedaliero-Universitaria Policlinico di Modena, Modena, Italy.

Claire Senechal (C)

Cancer Genetics Unit, Bergonie Institute, Bordeaux, France.

Gianmaria Miolo (G)

Department of Medical Oncology, Centro di Riferimento Oncologico di Aviano, IRCCS, Aviano, Italy.

Katarzyna Pogoda (K)

Department of Breast Cancer and Reconstructive Surgery, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland.

Jose Alejandro Pérez-Fidalgo (JA)

Department of Medical Oncology, INCLIVA University Hospital of Valencia, CIBERONC, Valencia, Spain.

Laura De Marchis (L)

Division of Medical Oncology, Department of Radiological, Oncological and Pathological Sciences, "La Sapienza" University of Rome, Rome, Italy.

Riccardo Ponzone (R)

Gynecological Oncology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo, Turin, Italy.

Luca Livraghi (L)

Medical Oncology Unit, ASST Papa Giovanni XXIII, Bergamo, Italy.
University of Siena, Siena, Italy.

Maria Del Pilar Estevez-Diz (MDP)

Department of Oncology, Instituto do Cancer do Estado de São Paulo-Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.

Cynthia Villarreal-Garza (C)

Departamento de Investigacion y de Tumores Mamarios, Instituto Nacional de Cancerologia, Mexico City, Mexico.
Tecnologico de Monterrey, Centro de Cancer de Mama del Hospital Zambrano Hellion, Nuevo Leon, Mexico.

Maria Vittoria Dieci (MV)

Department of Surgery, Oncology and Gastroenterology, University of Padova, Padova, Italy.
Medical Oncology 2, Istituto Oncologico Veneto IOV-IRCCS, Padova, Italy.

Florian Clatot (F)

Department of Medical Oncology, Centre Henri Becquerel, Rouen, France.

Martine Berlière (M)

Department of Oncology, Breast Clinic, Cliniques Universitaires Saint-Luc UCL, Brussels, Belgium.

Rossella Graffeo (R)

Breast Unit of Southern Switzerland, Oncology Institute of Southern Switzerland, Bellinzona, Switzerland.

Luis Teixeira (L)

Breast Disease Unit Saint-Louis Hospital, APHP, Université de Paris, Inserm, U976 HIPI Unit, F-75010, Paris, France.

Octavi Córdoba (O)

Obstetrics and Gynecology Department, Hospital Universitari Son Espases, Palma, Spain.

Amir Sonnenblick (A)

Oncology Division, Tel Aviv Sourasky Medical Center, and Sackler Faculty of Medicine, Tel Aviv, Israel.

Helena Luna Pais (H)

Department of Medical Oncology, Centro Hospitalar Universitário Lisboa Norte-Hospital de Santa Maria, Lisbon, Portugal.

Michail Ignatiadis (M)

Department of Medical Oncology, Institut Jules Bordet and Université Libre de, Brussels, Belgium.

Marianne Paesmans (M)

Data Centre, Institut Jules Bordet and Université Libre de Bruxelles, Brussels, Belgium.

Ann H Partridge (AH)

Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.

Olivier Caron (O)

Département Médecine Oncologique, Institut Gustave Roussy, Université Paris-Saclay, Villejuif, France.

Claire Saule (C)

Department of Genetics, Institut Curie, Paris, France.

Lucia Del Mastro (L)

Department of Internal Medicine and Medical Specialties (DiMI), School of Medicine, University of Genoa, Genoa, Italy.
Breast Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.

Fedro A Peccatori (FA)

Gynecologic Oncology Department, European Institute of Oncology IRCCS, Milan, Italy.

Hatem A Azim (HA)

Tecnologico de Monterrey, Centro de Cancer de Mama del Hospital Zambrano Hellion, Nuevo Leon, Mexico.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Personnes › Tranches d'âge › Adulte › Pregnancy After Breast Cancer in Patients With Germline
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Facteurs de transcription › Protéine BRCA1 › Pregnancy After Breast Cancer in Patients With Germline
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines nucléaires › Protéine BRCA2 › Pregnancy After Breast Cancer in Patients With Germline
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › Pregnancy After Breast Cancer in Patients With Germline
questionsmedicales.fr › Malformations et maladies congénitales, héréditaires et néonatales › Malformations › Pregnancy After Breast Cancer in Patients With Germline
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Analyse de survie › Survie sans rechute › Pregnancy After Breast Cancer in Patients With Germline
questionsmedicales.fr › Phénomènes génétiques › Variation génétique › Mutation › Mutation germinale › Pregnancy After Breast Cancer in Patients With Germline
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Pregnancy After Breast Cancer in Patients With Germline
questionsmedicales.fr › Phénomènes physiologiques des appareils urinaire et reproducteur › Phénomènes physiologiques de la reproduction › Reproduction › Grossesse › Issue de la grossesse › Naissance vivante › Pregnancy After Breast Cancer in Patients With Germline
questionsmedicales.fr › Phénomènes physiologiques des appareils urinaire et reproducteur › Phénomènes physiologiques de la reproduction › Reproduction › Grossesse › Pregnancy After Breast Cancer in Patients With Germline
questionsmedicales.fr › Maladies urogénitales › Maladies de l'appareil urogénital féminin et complications de la grossesse › Complications de la grossesse › Pregnancy After Breast Cancer in Patients With Germline
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Collecte de données › Registre civil › Taux de grossesse › Pregnancy After Breast Cancer in Patients With Germline
questionsmedicales.fr › Caractéristiques de la population › Santé › Santé reproductive › Pregnancy After Breast Cancer in Patients With Germline
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Caractéristiques des études épidémiologiques › Études épidémiologiques › Études de cohortes › Études rétrospectives › Pregnancy After Breast Cancer in Patients With Germline
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Probabilité › Risque › Appréciation des risques › Pregnancy After Breast Cancer in Patients With Germline
questionsmedicales.fr › Environnement et santé publique › Santé publique › Méthodes épidémiologiques › Statistiques comme sujet › Probabilité › Risque › Facteurs de risque › Pregnancy After Breast Cancer in Patients With Germline
questionsmedicales.fr › Phénomènes physiques › Temps › Facteurs temps › Pregnancy After Breast Cancer in Patients With Germline